



Market Announcement

20 July 2020

Zelira Therapeutics Limited (ASX: ZLD) – Trading Halt

Description

The securities of Zelira Therapeutics Limited ('ZLD') will be placed in trading halt at the request of ZLD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 July 2020 or when the announcement is released to the market.

Issued by

Madeleine Green

Senior Adviser, Listings Compliance (Perth)

20 July 2020

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000
Attention: Sean Maloney
By email only: sean.maloney@asx.com.au

Dear Sir,

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelira Therapeutics Limited ('the Company', ASX: **ZLD**) requests the granting of a trading halt in ZLD's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to a licencing agreement in the United States of America;
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Wednesday, 22 July 2020 or the making of an announcement in respect to the licencing agreement in the United States of America; and
3. ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely



Tim Slate
Company Secretary

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The Company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking product development programs targeting specific conditions (e.g. HOPE™) and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.

The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

The Company has developed two proprietary formulations (HOPE™) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products.